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Abstract: Although cellular RNA is subjected to the same oxidative insults as DNA and 
other cellular macromolecules, oxidative damage to RNA has not been a major focus in 
investigations of the biological consequences of free radical damage. In fact, because it is 
largely single-stranded and its bases lack the protection of hydrogen bonding and binding 
by specific proteins, RNA may be more susceptible to oxidative insults than is DNA. 
Oxidative damage to protein-coding RNA or non-coding RNA will, in turn, potentially 
cause errors in proteins and/or dysregulation of gene expression. While less lethal than 
mutations in the genome, such sublethal insults to cells might be associated with 
underlying mechanisms of several chronic diseases, including neurodegenerative disease. 
Recently, oxidative RNA damage has been described in several neurodegenerative 
diseases including Alzheimer disease, Parkinson disease, dementia with Lewy bodies, and Int. J. Mol. Sci. 2008, 9              
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prion diseases. Of particular interest, oxidative RNA damage can be demonstrated in 
vulnerable neurons early in disease, suggesting that RNA oxidation may actively 
contribute to the onset of the disease. An increasing body of evidence suggests that, 
mechanistically speaking, the detrimental effects of oxidative RNA damage to protein 
synthesis are attenuated, at least in part, by the existence of protective mechanisms that 
prevent the incorporation of the damaged ribonucleotides into the translational machinery. 
Further investigations aimed at understanding the processing mechanisms related to 
oxidative RNA damage and its consequences may provide significant insights into the 
pathogenesis of neurodegenerative and other degenerative diseases and lead to better 
therapeutic strategies. 
Keywords:  Alzheimer disease, 8-oxoguanosine, neurodegeneration, oxidative damage, 
Parkinson disease, RNA 
 
1.  Introduction 
 
Neurodegenerative diseases are common and are strictly age-associated; for example, the 
prevalence in the United States per 1,000 elderly is 65 for Alzheimer disease (AD) and 9.5 for 
Parkinson disease (PD), while the annual incidence per 1,000,000 of general population is 1.6 for 
amyotrophic lateral sclerosis (ALS) [1]. Many lines of evidence indicate that oxidative damage is 
involved in the pathogenesis of neurodegenerative diseases including AD, PD, and ALS [2-9]. Indeed, 
oxidatively modified products of nucleic acids (e.g., 8-oxodeoxyguanosine, 8-oxoguanosine) and 
proteins (e.g., 3-nitrotyrosine, protein carbonyls), as well as products of lipid peroxidation (e.g., 4-
hydroxynonenal, F2-isoprostane, malondialdehyde) and glycoxidation (e.g., carboxymethyl-lysine, 
pentosidine), all known markers of oxidative damage, have been demonstrated in central nervous 
system lesions, and in ante-mortem cerebrospinal fluid, serum, and urine from patients with these 
diseases [2-9]. The increased levels of oxidative damage in such neurodegenerative diseases are often 
accompanied by the concomitantly reduced levels of anti-oxidative defense mechanisms in the same 
subjects [3, 5]. Remarkably, a number of genetic and environmental factors, namely disease-specific 
gene mutations, risk-modifying gene polymorphisms, and risk-modifying life-style factors are closely 
associated with oxidative damage [3, 6, 9], yet interventions such as the administration of one or 
several antioxidants have been, at best, only modestly successful in clinical trials. The complexity of 
reactive oxygen species (ROS) metabolism thus suggests that the interventions to date have been too 
simplistic. Instead, more integrated approaches may be required to not only enrich the exogenous 
antioxidants but also to up-regulate the endogenous anti-oxidative defense systems [8, 9]. Clearly, 
there is a considerable need for a better understanding of the association between ROS metabolism and 
neurodegeneration, particularly with respect to RNA oxidation, and whether amelioration of RNA 
oxidation comprises an effective avenue to treatment, experimentally and clinically. 
Although RNA is subject to the same oxidative insults as DNA and other cellular macromolecules, 
oxidative damage to RNA has not been a major focus in oxidative stress studies. This is somewhat Int. J. Mol. Sci. 2008, 9              
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surprising since RNA is largely single-stranded and, its bases not being protected by hydrogen bonding 
or binding proteins, it is, in theory, more susceptible to oxidative insults than DNA [10-13]. It might 
also be noted that the relative abundance of RNA and its subcellular distribution in the immediate 
vicinity of mitochondria suggest an additional level of RNA vulnerability to ROS [10]. Given these 
factors, it is not surprising that, using high-performance liquid chromatography coupled with 
electrochemical detector (HPLC-ECD) or with electrospray tandem mass spectrometry (HPLC-
MS/MS), greater oxidation of RNA than of DNA has been shown [14] in both cell lines and tissues, 
including human leukocytes [15], human skin fibroblasts [16], human lung epithelial cells [17] and in 
rat liver [14, 18]. Moreover, urinary excretion of an oxidized form of ribonucleoside in healthy humans 
and rats [19] not only suggests substantial RNA oxidation in normal metabolism but also the existence 
of a repair mechanism for the damaged RNA. 
It is now evident that RNA molecules are not only intermediates for the transfer of genetic 
information but also key players in many mechanisms controlling the expression of genetic 
information [20-23]. Given that our understanding of RNAs is undergoing a “renaissance,” we and 
others have developed a hypothesis that RNA damage is involved in the pathogenesis of 
neurodegenerative diseases [10-12, 21-23]. Here we review recent studies demonstrating RNA 
oxidation in several neurological diseases and discuss the biological significance of such damage to 
RNA, as well as possible cellular mechanisms of repair against this damage. 
Figure 1. RNA Susceptibility to Oxidation is Sublethal Resulting in Chronic Neurodegeneration. 
Why is RNA oxidized?                   How is RNA oxidized?          What happens after RNA oxidation?
Single-Stranded
Abundant in Cells
Subcellular Distribution
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2. Significance of RNA Studies in Neurodegenerative Disease Research 
 
Recent progress in genetics has revealed an expansion of the role of RNA beyond its classical 
function in the “Central Dogma.” It is now evident that only a minority of genetic transcripts (2-3% in 
human) code for proteins. Non-coding RNA (ncRNA), rather than being cast aside as “junk,” functions 
directly in structural and catalytic activities and also plays a critical role in regulating the timing and 
rate of gene expression [20-23]. Of particular note, the complexity of an organism correlates poorly 
with the number of protein coding genes; however, complexity is highly correlated with the number of 
ncRNAs [24]. Furthermore, the increasing variety of ncRNAs being identified in the CNS suggests a 
strong connection between the biogenesis, dynamics of action, and combinational regulatory potential 
of ncRNAs and the complexity of the CNS [22, 23]. Therefore, further advances in studies on the 
mechanisms and consequences of RNA damage and its surveillance may have a significant impact on Int. J. Mol. Sci. 2008, 9              
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our understanding of the pathophysiology of currently unresolved complex diseases including 
neurological and psychiatric diseases [22-25]. 
In familial forms of two of the most common neurodegenerative diseases, AD and PD [1], germline 
mutations cause familial autosomal dominant disease with specific protein aggregates (e.g., amyloid-β 
in AD and α-synuclein in PD) that form hallmark lesions in affected brains, suggesting a possible 
etiological role of the protein aggregates in disease [8, 26]. However, the vast majority of the patients 
with AD and PD have no known germline mutations, prompting investigations into other upstream 
events. As we have reviewed here, oxidative damage to neuronal RNA is not only a common feature of 
AD, PD, and associated neurodegenerative diseases, but is also an early event, suggesting involvement 
of RNA damage as a primary pathogenic mechanism. Interestingly, RNA damage is less lethal for cells 
than mutations in genomic DNA, raising the novel possibility of sublethal RNA oxidation as an 
underlying mechanism of chronic disease and, in particular, neurodegenerative disease. 
 
3. RNA Oxidation in Various Neurological Diseases 
 
The disruption of transcriptional or translational fidelity in neurons leads to the accumulation of 
aberrant or misfolded proteins and neuronal death [27, 28]. Oxidative damage to DNA has been well 
studied and several classes of products such as base oxidation and fragmentation products (e.g., single- 
and double-strand breaks), inter/intra-strand cross-links, DNA-protein cross-links, and sugar 
fragmentation products have been identified [29, 30]. However, few studies have focused on oxidative 
damage to RNA and only limited kinds of oxidatively modified bases in RNA have been reported 
previously [31-36]. Among multiple adducts of nucleoside oxidation, adducts of deoxyguanosine and 
guanosine, i.e., 8-oxodeoxyguanosine (8-OdG) and 8-oxoguanosine (8-OG) are two of the best 
characterized and studied forms of DNA and RNA oxidation, respectively [14-18]. 
The availability of specific antibodies to 8-OdG and 8-OG has enabled us to perform in situ 
examination of nucleoside oxidation in postmortem brain tissue [37, 38]. In 1999, increased levels of 
8-OdG/8-OG were demonstrated in the vulnerable neuronal populations in postmortem brains of 
patients with AD and PD [10, 39].  In AD and PD, the neuronal 8-OdG/8-OG showed cytoplasmic 
predominance, which suggested either mitochondrial DNA or cytoplasmic RNA as major targets of 
oxidative damage. Because the neuronal 8-OdG/8-OG immunoreactivities in AD brain were 
diminished greatly by RNase pretreatment but not by DNase pretreatment, we concluded that the 
oxidized nucleoside was predominantly associated with RNA rather than DNA [10]. This idea was 
further supported by the immunoelectron microscopic observation that most of the oxidized nucleoside 
was localized to ribosomes [40]. 
Similar RNA oxidation was also observed in brain samples of patients with Down syndrome [41], 
dementia with Lewy bodies [42], Creutzfeldt-Jakob disease [43], and subacute sclerosing 
panencephalitis [44]. The oxidative damage to RNA was demonstrated not only in sporadic-forms of 
the diseases but also in familial-forms of AD [45] and prion diseases, e.g., familial Creutzfeldt-Jakob 
disease and Gerstmann-Strausler-Scheinker disease [43, 46]. Moreover, nuclear DNA oxidation and 
cytoplasmic RNA oxidation were observed in brains of patients with a genetic defect of nucleotide 
excision repair, xeroderma pigmentosum, a condition that manifests clinically in its hypersensitivity to 
sunlight and progressive neurological disease [47]. Additionally, RNA oxidation was demonstrated in Int. J. Mol. Sci. 2008, 9              
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muscle cells of patients with rimmed vacuole myopathy [48], a neuromuscular disease characterized 
by accumulation of proteins associated with neurodegenerative disease. RNA oxidation was also seen 
in smooth muscle and endothelial cells of atherosclerotic plaques [49], which are a known risk for AD 
pathology. In aged human skeletal muscle, a recent study has also demonstrated increased RNA 
oxidation, possibly related to increased levels of non-heme iron [50]. These findings further the 
concept that RNA oxidation is involved in chronic neurodegeneration. 
Our immunocytochemical studies of neuronal RNA oxidation were followed by biochemical 
detection of the oxidized nucleoside in AD brain with immunoblot analysis [51-55]. Shan et al. [51, 
55] used northwestern blotting, a method for detecting oxidized RNA using specific antibody, in this 
case, monoclonal anti-8-OG antibody, and showed that a significant amount of brain poly (A)+ mRNA 
species were oxidized in AD. The oxidation of mRNA was confirmed by cDNA synthesis and 
Southern blotting of the immunoprecipitated mRNA species. Densitometric analysis of the Southern 
blot results revealed that 30-70% of the mRNAs from AD frontal cortices were oxidized, while only 
2% of the mRNAs were oxidized in age-matched controls [55]. Interestingly, reverse transcription 
polymerase chain reaction (RT-PCR) and filter array analyses of the identified oxidized mRNAs 
revealed that, while some species were more susceptible to oxidative damage in AD, no common 
motifs or structures were found in the oxidatively susceptible mRNA species. Some of the identified 
known oxidized transcripts were related to AD, which included p21ras, mitogen-activated protein 
kinase (MAPK) kinase 1, carbonyl reductase, copper/zinc superoxide dismutase (SOD1), 
apolipoprotein D, calpains, but not amyloid-β protein precursor or tau [51]. Although these studies by 
Shan et al. [51, 55] focused on mRNA species, Honda et al. [52] and Ding et al. [53, 54] reported that 
ribosomal RNA (rRNA), extremely abundant in neurons, contained 8-OG in AD brain. Remarkably, 
rRNA showed higher binding capacity to redox-active iron than transfer RNA (tRNA), and 
consequently the oxidation of rRNA by the Fenton reaction formed 13 times more 8-OG than that 
formed with tRNA [52]. 
Of note, both immunocytochemical [9, 10, 39, 42] and biochemical [51, 53] studies revealed that 
the regional distribution of RNA oxidation in the brain correlated with the selective neuronal 
vulnerability in each neurological disease. There were increased levels of 8-OG in the hippocampus 
and cerebral neocortex in AD and in the substantia nigra in PD, while no alteration in 8-OG levels was 
found in the cerebellum in either AD or PD compared with controls [9, 10, 39, 51, 53]. 
Immunocytochemical analysis further indicated that the oxidized RNAs were more abundant in 
neuronal cells compared with glial cells [10, 39-42, 45]. 
In addition to the brain, significantly increased levels of the oxidized RNA nucleoside, 8-OG, have 
been identified in cerebrospinal fluid from patients with AD and PD [56-58] as well as in serum of PD 
patients [57], suggesting 8-OG as a possible biomarker for these diseases. As we describe in the 
following section, 8-OG may have diagnostic utility as a marker of early stage disease. 
 
4. Experimental Models 
 
Experimental studies in rodents have shown that neuronal RNA oxidation (8-OG) and spatial 
memory deficit are observed in older animals [59] as well as animals with intermittent hypoxia [60]. In 
both the aging and the hypoxia models, antioxidants or mitochondrial metabolites can reduce oxidative Int. J. Mol. Sci. 2008, 9              
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damage and the spatial memory deficit. C57BL/6J mice, including young mice (10-12 weeks old), 
show substantially increased levels of spontaneously oxidized RNA (8-OG) in neurons of the 
hippocampus and the substantia nigra [61], which contrasts with human control brains that show no 
apparent level of RNA oxidation at younger ages [10]. It would be interesting to see whether RNA 
oxidation differs among other mammalian species, particularly at the outer limit of species lifespan, 
since this time point tends to negatively correlate with levels of DNA oxidation [62]. 
Animal models of neurodegeneration via neurotoxins demonstrate RNA oxidation. Animals treated 
with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), for example, show degeneration in 
nigrostriatal dopaminergic neurons [63] and a significant increase in neuronal 8-OG in the substantia 
nigra [61]. In addition, a kainic acid-mediated excitotoxic model for neurodegeneration [64] is 
associated with increased levels of 8-OG in hippocampal neurons and glial cells [65]. 
A strong genetic link between oxidative damage and neurodegeneration has been suggested by the 
finding that about 20% of patients with familial ALS carry a mutation in SOD1, a metalloenzyme that 
catalyzes the dismutation of the toxic superoxide (O2•-) to hydrogen peroxide (H2O2) [66]. Although 
the prevailing hypothesis in SOD1 ALS suggests a toxic gain of function [5], a transgenic mouse 
model of ALS expressing Gly93Ala-SOD1 mutation [67] shows increased RNA oxidation in the motor 
neurons of the spinal cord [55, 68]. 
Cell culture experiments further suggest an association between increased RNA oxidation and 
neurodegeneration [69, 70]. In a mixed astrocyte and neuron culture model [69], DNA and RNA 
oxidation have been observed following proteasome inhibition, a biochemical abnormality commonly 
observed in neurodegenerative disease. Interestingly, in this model, neurons demonstrated larger 
increases in nucleic acid oxidation compared to astrocytes, and RNA appeared to undergo a greater 
degree of oxidation than DNA, a finding similar to the AD brain [10].  
Various neurodegenerative diseases including AD, PD, and ALS are associated with defects in the 
ubiquitin-proteasome system which has been shown to affect multiple aspects of RNA metabolism 
[71]. Another recent study using primary rat cortical cultures has shown that exposures to oxidative 
stress causes neuronal RNA oxidation and subsequent neuronal death [70], suggesting again an 
upstream role of neuronal RNA oxidation in the process of neurodegeneration. 
 
5. Time Course of RNA Oxidation 
 
The involvement of RNA oxidation in a variety of neurological diseases raises the possibility that 
this mechanism is epiphenomenal. In this respect, it should be noted that RNA oxidation is seen in 
early-stage AD [9, 40] as well as in a presymptomatic case with a familial AD mutation [45], Down 
syndrome cases with early-stage AD pathology [41], and subjects with mild cognitive impairment 
(MCI) [53, 54]. Moreover, the increased level of RNA oxidation in cerebrospinal fluid (CSF) is more 
prominent in AD and PD of short duration [56, 58] as well as in AD patients with higher scores on 
cognitive testing [56]. Recent studies of MCI subjects have also demonstrated increased 
oxidation/nitration to protein and lipid peroxidation [72, 73], increased lipid peroxidation in CSF, 
plasma, and urine [74], increased DNA oxidation in peripheral leukocytes [75], decreased plasma 
antioxidant vitamins and enzymes [76], and decreased plasma total antioxidant capacity [77]. In ALS, 
neuronal RNA oxidation has not been reported; however, significantly increased RNA oxidation has Int. J. Mol. Sci. 2008, 9              
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been observed in motor neurons in the presymptomatic stage in Gly93 Ala-SOD1 mice, the transgenic 
animal model of familial ALS [55, 68]. 
Of note, neuronal RNA oxidation is seen not only in early stage neurodegeneration but also in cases 
with subacute sclerosing panencephalitis, a condition caused by persistent measles virus infection and 
accompanied by neurofibrillary tangles [44]. From the standpoint of therapeutic intervention, early 
involvement of oxidative damage in disease pathogenesis provides a strategic target, as we have 
previously reviewed [9, 78, 79]. 
The relatively early chronological appearance of neuronal RNA oxidation is further suggested by a 
primary rat cortical culture model [70]. In the time course after various oxidative insults to the 
cultures, RNA oxidation occurs primarily in a distinct group of neurons that survive the insult but 
subsequently die in a delayed fashion. This finding models our hypothesis that RNA oxidation results 
in sublethal injury, predisposing to chronic neurodegeneration [70]. 
While protein carbonyls, lipid peroxidation products and glycoxidation products are relatively 
stable due to the formation of cross-links, oxidized RNAs are likely turned over more rapidly. On the 
other hand, RNA oxidation reflects the “steady-state balance” of oxidative damage at a “snapshot” 
point [10, 80]. In accordance with this concept, protein carbonyls, lipid peroxidation products such as 
4-hydroxynonenal and F2-isoprostane, and a glycoxidation product carboxymethyl-lysine have been 
demonstrated in neurons with and without associated pathology [81-84]. These data likely reflect the 
occurrence of damage throughout the early- and advanced-stages of neurodegeneration. These 
observations contrast remarkably with RNA oxidation, a “steady-state” marker that is prominent in 
neurons without pathology and is present in lesser amounts in neurons containing pathology [40, 41].  
3-Nitrotyrosine may be another steady-state marker of oxidative damage. 3-Nitrotyrosine is formed 
by a modification of tyrosine residue of proteins by an attack of peroxynitrite  (ONOO-), a powerful 
oxidant produced from the reaction of O2•
- with nitric oxide (NO•), and is not known to accumulate in 
cells. As such, it is not surprising that intracellular level of 3-nitrotyrosine parallels the level of 8-OG 
in AD and Down syndrome brains [40, 41]. 
 
6. Types of Reactive Oxygen Species and Relevance to RNA 
 
The brain is especially vulnerable to oxidative damage because of its high content of unsaturated 
fatty acids, high oxygen consumption rate and relative paucity of antioxidant enzymes compared with 
other organs [85, 86]. Given this environment, neurons are continuously exposed to ROS such as O2•
-, 
H2O2, and hydroxyl radical (•OH) that are produced by cellular respiration [85-87]. •OH, on the other 
hand, can diffuse through tissue only in the order of several nanometers [88] and O2•
- is minimally 
permeable through cell membranes [89]. Generally speaking, it is thought that cytoplasmic RNA is a 
major target of •OH while highly diffusible H2O2 [90] reacts with redox-active metals through the 
Fenton reaction [52] to damage DNA. 
In the AD brain, disrupted mitochondria likely also play a central role in producing abundant ROS 
and supplying redox-active iron into the cytosol [8, 91-93]. Indeed, ribosomes purified from AD 
hippocampus contain significantly higher levels of redox-active iron compared to controls, and the 
iron, in turn, is bound to rRNA [52]. Mitochondrial abnormalities coupled with metal dysregulation of 
metal homeostasis may therefore be key features closely associated with RNA oxidation in AD [94]. Int. J. Mol. Sci. 2008, 9              
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Interestingly, mitochondrial abnormalities [95, 96] and metal ion dysregulation [97, 98] are also found 
in the substantia nigra of PD, suggesting a common theme in neurodegenerative disease. 
 
7. Pathogenic Cascade Initiated by RNA Oxidation 
 
More than 20 different types of oxidatively altered purine and pyrimidine bases have been detected 
in nucleic acids [29, 30, 36, 99]. However, since guanine is the most reactive of the nucleic acid bases 
[33], it is not surprising that 8-hydroxyguanine is the most abundant [12]. The 8-hydroxyguanine-
containing nucleoside, 8-OG, can be formed in RNA by direct oxidation of the base and also by the 
incorporation of the oxidized base from the cytosolic pool into RNA through the normal action of 
RNA polymerase [33, 99]. 8-OG, as well as 8-hydroxyadenosine, 5-hydroxycytidine, and 5-
hydroxyuridine, have been identified in oxidized RNA [33], which may alter the pairing capacity and 
thus comprise the biochemical basis for erroneous translation, with 8-hydroxyguanine pairing with 
both adenine and cytosine [99, 100]. 
The biological consequence of oxidatively damaged mRNA species has been investigated in vitro 
by expressing oxidized mRNA species in cell lines. Oxidized mRNAs lead to loss of protein level and 
function, and potentially produce defective proteins leading to protein aggregation [51]. In a recent 
study, polyribosome analysis indicates that oxidized bases in mRNAs cause ribosome “stalling”, which 
leads to a decrease of protein expression [70]. When oxidized and non-oxidized luciferase RNAs were 
subjected to translation in rabbit reticulocyte lysates and analyzed by northern blot, the oxidized RNA 
samples showed decreased free monosomes and increased RNA-associated polyribosomes compared 
to the non-oxidized RNA samples [70]. In another recent study, the translation of oxidized mRNA in 
cell lines caused accumulation of short polypeptides, due to premature termination of translation of the 
oxidixed mRNA and/or proteolytic degradation of the modified protein containing the translation 
errors [101]. Coincidently, oxidative damage to Escherichia coli 16S rRNA results in the formation of 
short cDNA by the RT-PCR [102]. The biological consequences of ribosomal oxidation have been 
investigated in vitro using translation assays with oxidized ribosomes from rabbit reticulocytes and 
which demonstrate a significant reduction of protein synthesis [52]. Notably, studies on brains of 
subjects with AD and MCI have demonstrated ribosomal dysfunction associated with oxidative RNA 
damage [53, 54]. Isolated polyribosome complexes from AD and MCI brains further show a decreased 
rate of and capability for protein synthesis without alteration in the polyribosome content. Decreased 
rRNA and tRNA levels and increased 8-OG in total RNA pool, especially in rRNA, are accompanied 
by ribosomal dysfunction, while there is no alteration in the level of initiation factors [53]. These 
findings indicate that RNA oxidation has detrimental effects regardless of whether the damaged RNA 
species are coding for proteins (mRNA) or performing translation (rRNA and tRNA).  
It is noteworthy in this respect that studies on some anti-cancer agents have shown that RNA 
damage can lead to cell-cycle arrest and cell death, via a p53-dependent mechanism associated with 
inhibition of protein synthesis or p53-independent mechanism as yet uncharacterized [103]. 
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8. Repair Mechanisms 
 
Degradation of RNA plays a central role in cellular metabolism and damaged RNA can be removed 
through degradation by ribonucleases (RNase), but selective degradation of oxidized RNA has not 
been established for known RNases [11, 104]. Oxidative stress induces cytoplasmic mRNA processing 
bodies (so called P-bodies), the site of active degradation of mRNA [105, 106], which is coupled to 
induction of another cytoplasmic structure called the “stress granules” [107]. In contrast to mRNAs 
with rapid turnover, stable RNAs, consisting primarily of rRNAs and tRNAs and encompassing 98% 
of total cellular RNA, may be protected against RNase action by a protective tertiary structure, 
assembly into ribonucleoprotein complexes, or even blocking the RNA’s 3’ terminus [104]. 
  Until relatively recently, damaged RNA was thought to only be degraded and not repaired. 
However, Aas et al. [108] have suggested that cells have at least one specific mechanism to repair 
RNA damage [12, 103, 109]. Indeed, alkylation damage in RNA is repaired by the same mechanism as 
a DNA-repair, catalyzed in the bacterium Escerichia coli by the enzyme AlkB, and in humans by the 
related protein [108]. Alk B and its homologues hABH3 and hABH2 cause hydroxylation of the 
methyl group on damaged DNA and RNA bases, and thus directly reverse alkylation damage. Alk B 
and hABH3, but not hABH2, repair RNA, since Alk B and hABH3 prefer single-stranded nucleic 
acids while hABH2 acts more efficiently on double-stranded DNA [108]. DNA damage can be 
repaired not only by the mechanism of direct reversal of the modified bases but also by a base excision 
repair mechanism. Specific DNA glycosylases excise the damaged base and DNA polymerases replace 
the nucleotide [103, 110]. However, because the excision repair generally requires a complementary 
strand, the mechanism is not likely efficient in RNA [109]. 
Cells have mechanisms of dealing with nucleotide damage other than direct excision and repair, 
which seems to be useful for defense against oxidative damage to both DNA and RNA. Because 
oxidation of nucleotides can occur in the cellular nucleotide pool, and oxidized nucleotides can 
potentially be incorporated into DNA and RNA, the mechanism preventing incorporation of the 
oxidized nucleotide comes into play in coping with nucleic acid damage [11, 12, 103]. MutT protein in 
Escerichia coli and its mammalian homologues MutT homologue 1 (MTH1) and Nudix type 5 
(NUDT5) proteins participate in this error-avoiding mechanism by hydrolyzing the oxidized 
nucleoside diphosphates and /or triphosphates to the monophosphates [99, 100, 110-113]. Indeed, the 
increase in the production of erroneous proteins by oxidative damage is 28-fold over the wild type 
cells in Escerichia coli mutT deficient cells, which is reduced to 1.2- or 1.4-fold by the expression of 
MTH1 or NUDT5, respectively [99]. Correspondingly, MTH1 deficiency leads to increased levels of 
RNA oxidation products induced by kainic acid treatment in the MTH1-null mouse [65]. An increased 
expression of human MTH1 in the vulnerable neuronal populations has been demonstrated in post-
mortem brains of AD [114] and PD [115], which may indicate a compensatory up-regulation of the 
MTH1 against oxidative stress [112]. 
In addition to the hydrolyzing action of MTH1 and NUDT5, several other enzymes involved in 
nucleotide metabolism show discriminatory activity against the oxidized nucleotides. Guanylate kinase 
(GK), an enzyme that converts GMP to GDP, is inactive on 8-OH-GMP. Similarly, ribonucleotide 
reductase (RNR), an enzyme that catalyzes reduction of four naturally occurring ribonucleoside 
diphosphates, is inactive in converting 8-OH-GDP to 8-OH-dGDP thus preventing incorporation of the Int. J. Mol. Sci. 2008, 9              
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oxidized nucleotide into DNA synthesis [111]. On the other hand, nucleotide diphosphate kinase 
(NDK), an enzyme that converts GDP to GTP, fails to show such discriminating function [111]. The 
final “gatekeeper” discriminating the oxidized nucleotide from normal nucleotide is RNA polymerase 
that incorporates 8-OH-GTP into RNA at a much lower rate compared to normal GTP incorporation 
[11, 100]. 
One important unanswered question is whether cells have machinery to deal with oxidatively 
damaged nucleotides that are contained in RNA, since RNA can be directly oxidized even if the 
incorporation of oxidized nucleotides into RNA is blocked. Recently, proteins that bind specifically to 
8-OG-containing RNA have been reported, namely, Escerichia coli polynucleotide phosphorylase (Pnp) 
protein and human PNP [116, 117] as well as human Y box-binding protein 1 (YB-1) [118]. The 
binding of the specific protein likely makes the 8-OG-containing RNA resistant to nuclease 
degradation [116]. However, it has been proposed that these proteins may be able to recognize and 
distinguish the oxidized RNA molecule from normal ones, their binding thus contributing to the 
fidelity of translation in cells by sequestering the damaged RNA from the translational machinery 
[116-118].  
The human PNP protein binds preferentially to 8-OG-containing RNA and cellular amounts of 
human PNP protein decrease rapidly by exposure to agents inducing oxidative stress, while amounts of 
other proteins in the cells do not change after these treatments [118]. Recently, human YB-1 was 
demonstrated to be a component of P-bodies where active degradation of mRNA occurs. YB-1 is 
translocated from P-bodies to stress granules during oxidative stress, which suggests a dynamic link 
between P-bodies and stress granules under oxidative stress [119]. 
It is possible that RNA quality control mechanisms are defective or inefficient in cancer cells as 
well as cells of neurodegenerative diseases. Further elucidation of the mechanisms of repair or 
avoidance of RNA damage and their potential role in preventing human diseases might provide new 
approaches to therapy in a number of conditions that are so far untreatable.  
 
9. Conclusions 
 
Involvement of RNA oxidation in the process of neurodegeneration has been demonstrated in 
vulnerable neuronal population in neurodegenerative diseases such as AD and PD as well as in several 
cellular and animal models of neurodegeneration. Particular emphasis should be placed on the early-
stage involvement of RNA oxidation in the process of neurodegeneration, which suggests a primary 
role of RNA oxidation in the disease process. Indeed, oxidized RNA is associated with a disturbance 
in protein synthesis in vitro and in vivo. There are presently only a small number of studies suggesting 
the existence of coping mechanisms for RNA damage. The known mechanisms and the implications of 
their failure may be only the “tip of iceberg” of the role of sublethal RNA oxidation in chronic disease. 
Understanding the consequences and cellular handling mechanisms of oxidative RNA damage may 
provide clues to the pathophysiology of neurodegenerative diseases and form the basis for better 
therapeutic strategies.  
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